After rituximab, most people remain significantly immunocompromised for at least 6 months, with meaningful immune recovery typically taking 9 to 12 months after the last infusion. Some effects on the immune system can last even longer, particularly with repeated treatment cycles. The exact timeline depends on your underlying condition, how many doses you’ve received, and how quickly your body regenerates the immune cells that rituximab destroys.
How Rituximab Suppresses Your Immune System
Rituximab works by targeting and destroying B cells, a type of white blood cell responsible for producing antibodies. It locks onto a protein called CD20 on the surface of these cells and eliminates them through several pathways, including triggering the body’s own immune defenses against them. This happens fast: circulating B cells are essentially wiped out within 24 hours of the first infusion and remain nearly absent for weeks afterward.
The drug itself doesn’t stay in your system nearly as long as its effects do. During initial treatment cycles, rituximab clears from the blood rapidly, with a half-life as short as 27 hours. By the fourth cycle, the half-life extends to roughly 199 hours (about 8 days). But even after the drug is gone, B cells take months to grow back, which is why the immunosuppression lasts so much longer than the drug’s presence in your body.
The 6-to-12-Month Recovery Window
The first 6 months after your last rituximab infusion are the period of deepest immunosuppression. During this time, your B cell counts are at or near zero, and your ability to mount an antibody response to new infections or vaccines is severely limited. Research on vaccine responses confirms this: vaccinating within 6 months of rituximab produces virtually no antibody response.
B cells begin to repopulate gradually after the 6-month mark, but these early returning cells are immature and not yet fully functional. The 9-month point appears to be a meaningful milestone. Studies on COVID-19 vaccination found that a 9-month gap between the last rituximab dose and vaccination was the earliest interval that produced a reliable immune response, coinciding with the return of a specific subset of B cells called naïve B lymphocytes. These are the cells your body needs to recognize and respond to new threats.
For many people, functional immune recovery happens somewhere between 9 and 12 months. But this is an average, not a guarantee. Your doctor can track recovery through blood tests that measure CD19+ B cell counts, a marker that reflects how many B cells have returned to your circulation.
Infection Risk Is Highest in the First 3 Months
While the full immunocompromised period stretches for many months, the risk of serious opportunistic infections peaks early. A study of patients who developed Pneumocystis jirovecii pneumonia (a dangerous fungal lung infection) after rituximab found that every case occurred within 90 days of the last treatment. A separate report found a similar pattern, with all cases developing within 11 weeks.
During this high-risk window, practical precautions matter most. Avoid close contact with people who are visibly sick or have active infections. Wash your hands frequently. People in your household should not receive live vaccines (such as the nasal flu spray), and if they do, you should limit close contact with them or wear a mask. These precautions remain relevant throughout the full recovery period, though the urgency decreases as your B cells return.
Repeated Cycles Can Extend the Timeline
If you’ve had multiple rounds of rituximab, the immune suppression can deepen and last longer. One of the most significant long-term effects is a sustained drop in immunoglobulin G (IgG), the most abundant type of antibody in your blood. In a study of pediatric patients, 55% developed low IgG levels after rituximab treatment. Among those tracked for longer periods, about half still had low IgG levels more than 6 months later, and a small group of 9 patients remained antibody-deficient for over 5 years.
Low IgG doesn’t always cause symptoms, but it increases susceptibility to bacterial infections, particularly of the sinuses, lungs, and ears. Some patients with persistently low levels need immunoglobulin replacement therapy, which involves receiving donated antibodies through an IV or injection on a regular schedule. If you’ve had several courses of rituximab and find yourself getting frequent infections, IgG testing can help determine whether this is a factor.
Hepatitis B Reactivation Risk Lasts Years
One long-tail risk that extends well beyond the typical recovery window is hepatitis B reactivation. People who were previously exposed to hepatitis B, even if they cleared the virus and feel fine, carry a risk of the virus reactivating under rituximab’s immune suppression. In a study of rheumatoid arthritis patients with past hepatitis B exposure, 8% experienced reactivation, occurring anywhere from 6 months to 4 years after their last rituximab dose.
This is why screening for hepatitis B before starting rituximab is standard practice, and why antiviral preventive treatment is recommended for people with markers of past infection. If you fall into this category, viral monitoring should continue for at least 12 to 18 months after your last dose, and possibly longer depending on your specific risk factors.
Vaccines and Timing
Vaccines are one of the most practical ways the immunocompromised window affects daily life. The general rule is to avoid all live vaccines while B cells are depleted and for a period afterward. For non-live vaccines (like flu shots, COVID boosters, and tetanus), timing matters for effectiveness rather than safety. Getting vaccinated too soon after rituximab won’t harm you, but your body likely won’t build a meaningful response.
If you can safely delay your next rituximab cycle, aiming for at least 9 months between your last dose and vaccination gives you the best chance of a useful immune response. For people who can’t delay treatment that long, a 6-month minimum is a reasonable compromise, though the response will be weaker. Your doctor may check your B cell counts before vaccinating to see whether your immune system is ready to respond.
How to Track Your Recovery
Unlike many medications where you simply wait a set number of days, recovery from rituximab is measurable through blood work. The key marker is the CD19+ B cell count. When this number rises above your personal lowest point by a meaningful margin, it signals that repopulation has begun. Normal CD19+ B cell levels are roughly 0.4 to 1.0 × 10⁹ cells per liter, though you don’t necessarily need to reach the full normal range to have some functional immunity.
IgG levels are the other important number. Even after B cells return, your antibody levels may lag behind, especially after multiple treatment cycles. Checking both CD19+ counts and IgG levels together gives the clearest picture of where your immune system stands. If you’re planning surgery, travel, or vaccination, asking for these labs can help you and your doctor make better timing decisions.